AstraZeneca PLC (AZN) KPIs and segments
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của AstraZeneca · năm tài chính kết thúc December 31 (calendar fiscal year; FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
Nhìn nhanh KPI của AstraZeneca: 49 chỉ số vận hành, trong đó có Total revenue, Oncology — Worldwide product sales và Cardiovascular, Renal & Metabolism (CVRM), lấy từ 142 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
The Americas($M) | 42,201 | 38,544 | 34,754 | ||||||||||
Rest of Europe($M) | 41,596 | 37,884 | 40,638 | ||||||||||
United Kingdom($M) | 21,983 | 20,139 | 19,616 | ||||||||||
Asia, Africa And Australasia($M) | 8,294 | 7,468 | 6,111 | ||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)1 | |||||||||||||
Total revenue ($M)($M)7 | 15,384 | 15,288 | 15,503 | 15,191 | 14,457 | 13,588 | 14,891 | 13,565 | 12,938 | 12,679 | 12,024 | 11,492 | |
Product sales ($M)($M) | 14,510 | 14,386 | 14,538 | 14,365 | 13,795 | 12,875 | 13,362 | 12,947 | 12,452 | 12,177 | 11,323 | 11,018 | |
Alliance revenue ($M)($M)6 | 874 | 825 | 959 | 815 | 654 | 639 | 714 | 559 | 482 | 457 | 424 | 377 | |
Enhertu (Daiichi Sankyo alliance) revenue ($M)($M) | 550 | 508 | 507 | 457 | 436 | 392 | 361 | 344 | 339 | 281 | 266 | ||
Tezspire (Amgen alliance) revenue ($M)($M) | 218 | 154 | 220 | 168 | 155 | 133 | 123 | 104 | 77 | 80 | 74 | ||
Beyfortus (Sanofi / Sobi alliance) revenue ($M)($M) | 32 | 116 | 170 | 142 | 27 | 161 | 49 | 7 | 20 | 41 | |||
Datroway (Daiichi Sankyo alliance) revenue ($M)($M) | 51 | 42 | 39 | 24 | 10 | ||||||||
Other royalty income ($M)($M) | 22 | 29 | 22 | 24 | 21 | 18 | |||||||
Other alliance revenue ($M)($M) | 1 | 1 | 1 | 24 | 26 | 4 | 26 | 27 | 21 | 1 | 19 | ||
Collaboration revenue ($M)($M) | 0 | 77 | 6 | 11 | 8 | 74 | 815 | 59 | 4 | 45 | 277 | 97 | |
United States (US) — Total revenue ($M)($M)3 | 6,686 | 6,205 | 6,932 | 6,548 | 6,323 | 5,646 | 6,532 | 6,008 | 5,571 | 5,124 | 5,101 | 4,859 | |
United States (US) — Share of total revenue (%)(%) | 43.0% | 41.0% | 45.0% | 43.0% | 44.0% | 42.0% | 44.0% | 44.0% | 43.0% | 40.0% | 42.0% | 42.0% | |
United States (US) — Revenue YoY actual (%)(%) | 6.0% | 10.0% | 6.0% | 9.0% | 13.0% | 10.0% | 28.0% | 23.0% | 17.0% | 19.0% | 7.0% | 5.0% | |
United States (US) — Revenue YoY at constant exchange rates / CER (%)(%) | 6.0% | 10.0% | 6.0% | 9.0% | 14.0% | 10.0% | 28.0% | 23.0% | 17.0% | 19.0% | 6.0% | 4.0% | |
Emerging Markets — Total revenue ($M)($M)5 | 3,921 | 4,398 | 3,646 | 3,960 | 3,754 | 3,943 | 3,134 | 3,423 | 3,386 | 3,732 | 2,783 | 2,964 | |
Emerging Markets — Share of total revenue (%)(%) | 25.0% | 29.0% | 24.0% | 26.0% | 26.0% | 29.0% | 21.0% | 25.0% | 26.0% | 29.0% | 23.0% | 26.0% | |
Emerging Markets — Revenue YoY actual (%)(%) | 4.0% | 12.0% | 16.0% | 16.0% | 11.0% | 6.0% | 13.0% | 15.0% | 9.0% | 18.0% | 2.0% | 4.0% | |
Emerging Markets — Revenue YoY at constant exchange rates / CER (%)(%) | 0.0% | 6.0% | 14.0% | 15.0% | 13.0% | 12.0% | 19.0% | 23.0% | 18.0% | 26.0% | 8.0% | 12.0% | |
China — Total revenue ($M)($M)3 | 1,587 | 1,923 | 1,375 | 1,764 | 1,710 | 1,805 | 1,364 | 1,671 | 1,630 | 1,748 | 1,382 | 1,452 | |
China — Share of total revenue (%)(%) | 10.0% | 13.0% | 9.0% | 12.0% | 12.0% | 13.0% | 9.0% | 12.0% | 13.0% | 14.0% | 11.0% | 13.0% | |
China — Revenue YoY actual (%)(%) | -7.0% | 7.0% | 1.0% | 6.0% | 5.0% | 3.0% | -1.0% | 15.0% | 13.0% | 9.0% | 16.0% | -6.0% | |
China — Revenue YoY at constant exchange rates / CER (%)(%) | -13.0% | 2.0% | 1.0% | 5.0% | 5.0% | 5.0% | -3.0% | 15.0% | 18.0% | 13.0% | 16.0% | 1.0% | |
Emerging Markets excluding China — Total revenue ($M)($M)3 | 2,334 | 2,475 | 2,271 | 2,196 | 2,043 | 2,138 | 1,770 | 1,752 | 1,756 | 1,984 | 1,401 | 1,513 | |
Emerging Markets excluding China — Share of total revenue (%)(%) | 15.0% | 16.0% | 15.0% | 14.0% | 14.0% | 16.0% | 12.0% | 13.0% | 14.0% | 16.0% | 12.0% | 13.0% | |
Emerging Markets excluding China — Revenue YoY actual (%)(%) | 14.0% | 16.0% | 28.0% | 25.0% | 16.0% | 8.0% | 26.0% | 16.0% | 5.0% | 27.0% | -9.0% | 15.0% | |
Emerging Markets excluding China — Revenue YoY at constant exchange rates / CER (%)(%) | 11.0% | 9.0% | 24.0% | 25.0% | 21.0% | 17.0% | 42.0% | 31.0% | 18.0% | 40.0% | 2.0% | 25.0% | |
Europe — Total revenue ($M)($M)3 | 3,417 | 3,405 | 3,579 | 3,334 | 3,066 | 2,759 | 3,948 | 2,875 | 2,732 | 2,634 | 2,880 | 2,392 | |
Europe — Share of total revenue (%)(%) | 22.0% | 22.0% | 23.0% | 22.0% | 21.0% | 20.0% | 27.0% | 21.0% | 21.0% | 21.0% | 24.0% | 21.0% | |
Europe — Revenue YoY actual (%)(%) | 11.0% | 23.0% | -9.0% | 16.0% | 12.0% | 5.0% | 37.0% | 22.0% | 24.0% | 22.0% | 25.0% | 16.0% | |
Europe — Revenue YoY at constant exchange rates / CER (%)(%) | 7.0% | 9.0% | -15.0% | 10.0% | 8.0% | 9.0% | 35.0% | 22.0% | 24.0% | 19.0% | 17.0% | 9.0% | |
Established Rest of World (Japan, Canada, Australia & New Zealand) — Total revenue ($M)($M)3 | 1,361 | 1,280 | 1,345 | 1,349 | 1,315 | 1,239 | 1,277 | 1,260 | 1,249 | 1,189 | 1,259 | 1,276 | |
Established Rest of World (Japan, Canada, Australia & New Zealand) — Share of total revenue (%)(%) | 9.0% | 8.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 10.0% | 9.0% | 10.0% | 11.0% | |
Established Rest of World (Japan, Canada, Australia & New Zealand) — Revenue YoY actual (%)(%) | 4.0% | 3.0% | 5.0% | 7.0% | 5.0% | 4.0% | 1.0% | -1.0% | -5.0% | -5.0% | -9.0% | -10.0% | |
Established Rest of World (Japan, Canada, Australia & New Zealand) — Revenue YoY at constant exchange rates / CER (%)(%) | 8.0% | 2.0% | 7.0% | 5.0% | 2.0% | 9.0% | 2.0% | 4.0% | 6.0% | 2.0% | -6.0% | -6.0% | |
Oncology — Worldwide product sales ($M)($M)16 | 6,713 | 6,236 | 6,470 | 6,143 | 5,854 | 5,231 | 5,341 | 5,197 | 4,976 | 4,760 | 4,453 | 4,389 | |
Oncology — Worldwide YoY actual (%)(%) | 15.0% | 19.0% | 21.0% | 18.0% | 18.0% | 10.0% | 20.0% | 18.0% | 14.0% | 21.0% | 19.0% | 16.0% | |
Oncology — Worldwide YoY CER (%)(%) | 13.0% | 15.0% | 19.0% | 17.0% | 17.0% | 13.0% | 22.0% | 21.0% | 18.0% | 24.0% | 19.0% | 17.0% | |
Oncology — US product sales ($M)($M)1 | 3,163 | 2,788 | 3,128 | 2,893 | 2,770 | 2,397 | 2,640 | 2,484 | 2,302 | 2,084 | 2,067 | 1,986 | |
Oncology — US YoY (%)(%) | 14.0% | 16.0% | 18.0% | 16.0% | 20.0% | 15.0% | 28.0% | 25.0% | 17.0% | 22.0% | 16.0% | 16.0% | |
Oncology — Emerging Markets product sales ($M)($M)2 | 1,522 | 1,521 | 1,342 | 1,380 | 1,310 | 1,318 | 1,057 | 1,145 | 1,098 | 1,202 | 904 | 971 | |
Oncology — Emerging Markets YoY actual (%)(%) | 16.0% | 15.0% | 27.0% | 21.0% | 19.0% | 10.0% | 17.0% | 18.0% | 11.0% | 24.0% | 11.0% | 4.0% | |
Oncology — Emerging Markets YoY CER (%)(%) | 12.0% | 10.0% | 25.0% | 21.0% | 22.0% | 16.0% | 27.0% | 28.0% | 22.0% | 33.0% | 18.0% | 13.0% | |
Oncology — Europe product sales ($M)($M)2 | 1,408 | 1,378 | 1,381 | 1,284 | 1,183 | 1,032 | 1,082 | 1,032 | 1,015 | 953 | 903 | 849 | |
Oncology — Europe YoY actual (%)(%) | 19.0% | 34.0% | 28.0% | 24.0% | 17.0% | 8.0% | 20.0% | 22.0% | 24.0% | 26.0% | 31.0% | 22.0% | |
Oncology — Europe YoY CER (%)(%) | 14.0% | 18.0% | 19.0% | 17.0% | 12.0% | 12.0% | 18.0% | 22.0% | 24.0% | 23.0% | 22.0% | 15.0% | |
Oncology — Established RoW product sales ($M)($M)2 | 620 | 549 | 619 | 586 | 591 | 484 | 562 | 536 | 561 | 521 | 579 | 583 | |
Oncology — Established RoW YoY actual (%)(%) | 5.0% | 13.0% | 10.0% | 9.0% | 5.0% | -7.0% | -3.0% | -8.0% | -9.0% | 6.0% | 28.0% | 28.0% | |
Oncology — Established RoW YoY CER (%)(%) | 10.0% | 12.0% | 12.0% | 7.0% | 2.0% | -2.0% | -3.0% | -3.0% | 2.0% | 16.0% | 32.0% | 35.0% | |
Tagrisso (osimertinib) — Worldwide product sales ($M)($M)6 | 1,941 | 1,833 | 1,902 | 1,864 | 1,810 | 1,679 | 1,703 | 1,674 | 1,608 | 1,595 | 1,419 | 1,465 | |
Imfinzi (durvalumab) — Worldwide product sales ($M)($M)6 | 1,854 | 1,694 | 1,747 | 1,601 | 1,455 | 1,261 | 1,254 | 1,203 | 1,147 | 1,113 | 1,135 | 1,126 | |
Calquence (acalabrutinib) — Worldwide product sales ($M)($M)6 | 1,022 | 923 | 967 | 916 | 872 | 762 | 808 | 813 | 790 | 718 | 675 | 654 | |
Lynparza (olaparib) — Worldwide product sales ($M)($M)6 | 829 | 781 | 878 | 837 | 838 | 726 | 844 | 778 | 744 | 705 | 741 | 702 | |
Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M)($M)6 | 338 | 324 | 292 | 257 | 230 | 198 | 148 | 148 | 127 | 122 | 83 | 73 | |
Truqap (capivasertib) — Worldwide product sales ($M)($M)6 | 233 | 198 | 233 | 193 | 170 | 132 | 163 | 125 | 92 | 50 | 6 | ||
Zoladex (goserelin) — Worldwide product sales ($M)($M)6 | 304 | 304 | 254 | 285 | 284 | 283 | 242 | 268 | 273 | 276 | 254 | 239 | |
Imjudo (tremelimumab) — Worldwide product sales ($M)($M)6 | 83 | 77 | 93 | 84 | 89 | 80 | 73 | 72 | 74 | 62 | |||
Datroway (datopotamab deruxtecan — direct product sales) — Worldwide product sales ($M)($M)4 | 4 | 1 | 1 | ||||||||||
Other Oncology medicines — Worldwide product sales ($M)($M)6 | 102 | 101 | 103 | 106 | 106 | 110 | 97 | 106 | 109 | 107 | 50 | 54 | |
Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M)($M)14 | 2,771 | 3,240 | 3,044 | 3,214 | 3,261 | 3,245 | 3,132 | 3,152 | 3,153 | 3,012 | 2,698 | 2,683 | |
Cardiovascular, Renal & Metabolism (CVRM) — Worldwide YoY actual (%)(%) | -15.0% | 0.0% | -3.0% | 2.0% | 3.0% | 8.0% | 16.0% | 17.0% | 18.0% | 19.0% | 18.0% | 14.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Worldwide YoY CER (%)(%) | -18.0% | -6.0% | -6.0% | 0.0% | 3.0% | 12.0% | 17.0% | 20.0% | 22.0% | 22.0% | 18.0% | 16.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — US product sales ($M)($M)1 | 375 | 593 | 709 | 662 | 665 | 687 | 853 | 739 | 735 | 748 | 780 | 690 | |
Cardiovascular, Renal & Metabolism (CVRM) — US YoY (%)(%) | -44.0% | -14.0% | -17.0% | -10.0% | -10.0% | -8.0% | 9.0% | 7.0% | 11.0% | 20.0% | 12.0% | 9.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets product sales ($M)($M)2 | 1,346 | 1,653 | 1,270 | 1,559 | 1,512 | 1,552 | 1,193 | 1,396 | 1,384 | 1,365 | 1,078 | 1,161 | |
Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets YoY actual (%)(%) | -11.0% | 7.0% | 6.0% | 12.0% | 9.0% | 14.0% | 11.0% | 20.0% | 17.0% | 17.0% | 15.0% | 7.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets YoY CER (%)(%) | -15.0% | 0.0% | 4.0% | 11.0% | 11.0% | 20.0% | 14.0% | 25.0% | 24.0% | 24.0% | 19.0% | 15.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Europe product sales ($M)($M)2 | 887 | 868 | 895 | 806 | 889 | 807 | 886 | 826 | 843 | 716 | 679 | 657 | |
Cardiovascular, Renal & Metabolism (CVRM) — Europe YoY actual (%)(%) | 0.0% | 8.0% | 1.0% | -2.0% | 5.0% | 13.0% | 31.0% | 26.0% | 38.0% | 29.0% | 38.0% | 40.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Europe YoY CER (%)(%) | -4.0% | -5.0% | -6.0% | -8.0% | 1.0% | 17.0% | 28.0% | 26.0% | 38.0% | 26.0% | 28.0% | 32.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Established RoW product sales ($M)($M)2 | 163 | 126 | 170 | 187 | 195 | 199 | 200 | 191 | 191 | 183 | 161 | 175 | |
Cardiovascular, Renal & Metabolism (CVRM) — Established RoW YoY actual (%)(%) | -16.0% | -37.0% | -15.0% | -2.0% | 2.0% | 9.0% | 24.0% | 9.0% | -14.0% | -2.0% | 5.0% | 6.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Established RoW YoY CER (%)(%) | -12.0% | -38.0% | -13.0% | -4.0% | -2.0% | 13.0% | 24.0% | 14.0% | -3.0% | 7.0% | 8.0% | 10.0% | |
Farxiga / Forxiga (dapagliflozin) — Worldwide product sales ($M)($M)6 | 1,804 | 2,193 | 2,059 | 2,134 | 2,150 | 2,057 | 1,933 | 1,938 | 1,940 | 1,845 | 1,606 | 1,554 | |
Lokelma (sodium zirconium cyclosilicate) — Worldwide product sales ($M)($M)6 | 221 | 199 | 181 | 189 | 175 | 153 | 150 | 143 | 136 | 114 | 112 | 102 | |
Brilinta / Brilique (ticagrelor) — Worldwide product sales ($M)($M)6 | 80 | 105 | 158 | 146 | 215 | 305 | 341 | 327 | 342 | 323 | 329 | 331 | |
Crestor (rosuvastatin) — Worldwide product sales ($M)($M)6 | 331 | 354 | 275 | 305 | 319 | 316 | 261 | 304 | 292 | 297 | 247 | 275 | |
Seloken / Toprol-XL (metoprolol) — Worldwide product sales ($M)($M)6 | 157 | 180 | 139 | 160 | 148 | 161 | 140 | 150 | 150 | 165 | 144 | 153 | |
Roxadustat (evrenzo) — Worldwide product sales ($M)($M)6 | 14 | 43 | 47 | 77 | 72 | 78 | 74 | 93 | 88 | 75 | 63 | 74 | |
Wainua (eplontersen) — Worldwide product sales ($M)($M)6 | 70 | 51 | 69 | 59 | 44 | 39 | 42 | 23 | 16 | 5 | |||
Other CVRM medicines — Worldwide product sales ($M)($M)6 | 91 | 115 | 116 | 144 | 138 | 136 | 132 | 120 | 130 | 141 | 58 | 66 | |
Respiratory & Immunology (R&I) — Worldwide product sales ($M)($M)14 | 2,207 | 2,150 | 2,147 | 2,085 | 1,988 | 1,947 | 1,985 | 1,830 | 1,797 | 1,804 | 1,590 | 1,451 | |
Respiratory & Immunology (R&I) — Worldwide YoY actual (%)(%) | 11.0% | 10.0% | 8.0% | 14.0% | 11.0% | 8.0% | 25.0% | 26.0% | 21.0% | 14.0% | 10.0% | 2.0% | |
Respiratory & Immunology (R&I) — Worldwide YoY CER (%)(%) | 9.0% | 6.0% | 6.0% | 12.0% | 10.0% | 11.0% | 26.0% | 28.0% | 24.0% | 16.0% | 10.0% | 3.0% | |
Respiratory & Immunology (R&I) — US product sales ($M)($M)1 | 982 | 880 | 984 | 1,013 | 977 | 865 | 996 | 852 | 830 | 737 | 647 | 609 | |
Respiratory & Immunology (R&I) — US YoY (%)(%) | 0.0% | 2.0% | -1.0% | 19.0% | 18.0% | 17.0% | 54.0% | 40.0% | 23.0% | 19.0% | -6.0% | -8.0% | |
Respiratory & Immunology (R&I) — Emerging Markets product sales ($M)($M)2 | 490 | 565 | 468 | 445 | 381 | 529 | 408 | 457 | 444 | 588 | 456 | 422 | |
Respiratory & Immunology (R&I) — Emerging Markets YoY actual (%)(%) | 29.0% | 7.0% | 15.0% | -3.0% | -14.0% | -10.0% | -11.0% | 8.0% | 23.0% | 10.0% | 34.0% | 14.0% | |
Respiratory & Immunology (R&I) — Emerging Markets YoY CER (%)(%) | 24.0% | 2.0% | 12.0% | -3.0% | -13.0% | -6.0% | -7.0% | 14.0% | 34.0% | 16.0% | 41.0% | 23.0% | |
Respiratory & Immunology (R&I) — Europe product sales ($M)($M)2 | 509 | 498 | 477 | 425 | 422 | 378 | 391 | 346 | 350 | 330 | 317 | 266 | |
Respiratory & Immunology (R&I) — Europe YoY actual (%)(%) | 21.0% | 32.0% | 22.0% | 23.0% | 21.0% | 14.0% | 23.0% | 30.0% | 21.0% | 13.0% | 22.0% | 9.0% | |
Respiratory & Immunology (R&I) — Europe YoY CER (%)(%) | 16.0% | 17.0% | 14.0% | 16.0% | 16.0% | 19.0% | 21.0% | 30.0% | 21.0% | 11.0% | 14.0% | 2.0% | |
Respiratory & Immunology (R&I) — Established RoW product sales ($M)($M)2 | 226 | 207 | 218 | 202 | 208 | 175 | 190 | 175 | 173 | 149 | 170 | 154 | |
Respiratory & Immunology (R&I) — Established RoW YoY actual (%)(%) | 9.0% | 19.0% | 15.0% | 16.0% | 20.0% | 17.0% | 12.0% | 13.0% | 8.0% | 6.0% | 10.0% | 3.0% | |
Respiratory & Immunology (R&I) — Established RoW YoY CER (%)(%) | 11.0% | 15.0% | 17.0% | 15.0% | 19.0% | 24.0% | 12.0% | 18.0% | 14.0% | 11.0% | 12.0% | 7.0% | |
Fasenra (benralizumab) — Worldwide product sales ($M)($M)6 | 570 | 483 | 530 | 530 | 502 | 418 | 471 | 436 | 423 | 358 | 420 | 389 | |
Breztri Aerosphere (budesonide/glycopyrronium/formoterol) — Worldwide product sales ($M)($M)6 | 346 | 353 | 294 | 323 | 283 | 300 | 257 | 266 | 235 | 219 | 199 | 171 | |
Symbicort (budesonide/formoterol) — Worldwide product sales ($M)($M)6 | 671 | 747 | 704 | 742 | 715 | 723 | 684 | 705 | 722 | 769 | 520 | 555 | |
Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M)($M)6 | 172 | 149 | 141 | 119 | 112 | 87 | 80 | 68 | 57 | 43 | 35 | 21 | |
Saphnelo (anifrolumab) — Worldwide product sales ($M)($M)6 | 209 | 171 | 203 | 180 | 167 | 136 | 147 | 124 | 112 | 91 | 89 | 76 | |
Airsupra (albuterol/budesonide) — Worldwide product sales ($M)($M)4 | 50 | 37 | 51 | 45 | 42 | 28 | 25 | 21 | 14 | 7 | |||
Pulmicort (budesonide) — Worldwide product sales ($M)($M)6 | 120 | 149 | 161 | 93 | 106 | 158 | 164 | 138 | 155 | 224 | 219 | 148 | |
Other Respiratory & Immunology medicines — Worldwide product sales ($M)($M)6 | 69 | 61 | 63 | 53 | 61 | 97 | 157 | 72 | 79 | 93 | 80 | 67 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M)($M)9 | 99 | 90 | 272 | 274 | 157 | 143 | 378 | 355 | 112 | 212 | 345 | 224 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide YoY actual (%)(%) | -37.0% | -37.0% | -28.0% | -23.0% | 40.0% | -32.0% | 10.0% | 59.0% | 28.0% | -40.0% | -69.0% | -74.0% | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide YoY CER (%)(%) | -38.0% | -41.0% | -30.0% | -24.0% | 42.0% | -30.0% | 8.0% | 61.0% | 42.0% | -40.0% | -70.0% | -74.0% | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — US product sales ($M)($M)1 | 35 | 23 | 54 | 54 | 73 | 27 | 80 | 145 | 28 | 27 | 59 | 15 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — US YoY (%)(%) | -52.0% | -15.0% | -32.0% | -63.0% | 2.0% | 35.0% | -74.0% | -95.0% | |||||
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets product sales ($M)($M)2 | 31 | 40 | 59 | 40 | 38 | 83 | 45 | 37 | 41 | 90 | 31 | 32 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets YoY actual (%)(%) | -18.0% | -52.0% | 32.0% | 7.0% | -6.0% | -8.0% | 46.0% | 18.0% | -10.0% | -13.0% | -90.0% | -76.0% | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets YoY CER (%)(%) | -24.0% | -55.0% | 26.0% | 7.0% | -1.0% | -3.0% | 58.0% | 37.0% | 4.0% | -12.0% | -90.0% | -75.0% | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Europe product sales ($M)($M)2 | 9 | 16 | 153 | 152 | 24 | 26 | 219 | 108 | 7 | 74 | 195 | 122 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Europe YoY actual (%)(%) | -62.0% | -40.0% | -30.0% | 41.0% | -65.0% | 12.0% | 23.0% | -55.0% | -27.0% | -42.0% | -33.0% | ||
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Europe YoY CER (%)(%) | -64.0% | -47.0% | -33.0% | 37.0% | -64.0% | 9.0% | 20.0% | -53.0% | -26.0% | -45.0% | -35.0% | ||
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW product sales ($M)($M)2 | 24 | 11 | 6 | 28 | 22 | 7 | 34 | 65 | 36 | 21 | 60 | 55 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY actual (%)(%) | 7.0% | 67.0% | -82.0% | -57.0% | -39.0% | -67.0% | -43.0% | 18.0% | 36.0% | -87.0% | -76.0% | -78.0% | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY CER (%)(%) | 6.0% | 55.0% | -82.0% | -57.0% | -40.0% | -67.0% | -44.0% | 23.0% | 55.0% | -86.0% | -75.0% | -77.0% | |
Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M)($M)6 | 47 | 24 | 59 | 94 | 98 | 30 | 130 | 134 | 28 | 26 | 54 | 50 | |
FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M)($M)6 | 18 | 8 | 140 | 122 | 10 | 0 | 149 | 100 | 2 | 7 | 138 | 75 | |
Other Vaccines & Immune Therapies — Worldwide product sales ($M)($M)6 | 34 | 58 | 1 | 0 | 0 | 1 | -2 | 0 | 0 | 6 | |||
Rare Disease (Alexion) — Worldwide product sales ($M)($M)11 | 2,490 | 2,420 | 2,374 | 2,416 | 2,294 | 2,042 | 2,277 | 2,148 | 2,147 | 2,096 | 1,971 | 1,974 | |
Rare Disease (Alexion) — Worldwide YoY actual (%)(%) | 9.0% | 19.0% | 4.0% | 12.0% | 7.0% | -3.0% | 16.0% | 9.0% | 10.0% | 12.0% | 9.0% | 13.0% | |
Rare Disease (Alexion) — Worldwide YoY CER (%)(%) | 8.0% | 15.0% | 3.0% | 11.0% | 7.0% | 0.0% | 17.0% | 11.0% | 14.0% | 16.0% | 9.0% | 14.0% | |
Rare Disease (Alexion) — US product sales ($M)($M)1 | 1,452 | 1,372 | 1,424 | 1,415 | 1,346 | 1,237 | 1,421 | 1,325 | 1,311 | 1,207 | 1,232 | 1,179 | |
Rare Disease (Alexion) — US YoY (%)(%) | 8.0% | 11.0% | 0.0% | 7.0% | 3.0% | 3.0% | 15.0% | 12.0% | 10.0% | 10.0% | 7.0% | 9.0% | |
Rare Disease (Alexion) — Emerging Markets product sales ($M)($M)2 | 305 | 347 | 248 | 307 | 278 | 205 | 221 | 174 | 203 | 251 | 136 | 163 | |
Rare Disease (Alexion) — Emerging Markets YoY actual (%)(%) | 10.0% | 69.0% | 12.0% | 76.0% | 37.0% | -18.0% | 63.0% | 7.0% | 35.0% | 45.0% | 18.0% | 49.0% | |
Rare Disease (Alexion) — Emerging Markets YoY CER (%)(%) | 6.0% | 57.0% | 10.0% | 73.0% | 48.0% | -10.0% | 84.0% | 29.0% | 67.0% | 73.0% | 46.0% | 70.0% | |
Rare Disease (Alexion) — Europe product sales ($M)($M)2 | 442 | 431 | 422 | 410 | 412 | 360 | 379 | 395 | 392 | 401 | 364 | 397 | |
Rare Disease (Alexion) — Europe YoY actual (%)(%) | 7.0% | 20.0% | 11.0% | 4.0% | 5.0% | -10.0% | 4.0% | 0.0% | 3.0% | 4.0% | 4.0% | 15.0% | |
Rare Disease (Alexion) — Europe YoY CER (%)(%) | 3.0% | 6.0% | 4.0% | -2.0% | 1.0% | -7.0% | 2.0% | 0.0% | 3.0% | 1.0% | -3.0% | 8.0% | |
Rare Disease (Alexion) — Established RoW product sales ($M)($M)2 | 291 | 270 | 280 | 284 | 258 | 240 | 256 | 254 | 241 | 237 | 239 | 235 | |
Rare Disease (Alexion) — Established RoW YoY actual (%)(%) | 13.0% | 13.0% | 9.0% | 12.0% | 7.0% | 1.0% | 7.0% | 8.0% | 7.0% | 12.0% | 18.0% | 16.0% | |
Rare Disease (Alexion) — Established RoW YoY CER (%)(%) | 20.0% | 13.0% | 11.0% | 9.0% | 2.0% | 6.0% | 8.0% | 14.0% | 18.0% | 21.0% | 22.0% | 22.0% | |
Ultomiris (ravulizumab) — Worldwide product sales ($M)($M)6 | 1,314 | 1,270 | 1,265 | 1,225 | 1,177 | 1,050 | 1,089 | 1,031 | 946 | 859 | 825 | 777 | |
Soliris (eculizumab) — Worldwide product sales ($M)($M)6 | 389 | 389 | 401 | 462 | 530 | 444 | 543 | 606 | 700 | 739 | 715 | 781 | |
Strensiq (asfotase alfa) — Worldwide product sales ($M)($M)6 | 536 | 517 | 490 | 441 | 395 | 352 | 420 | 343 | 340 | 313 | 305 | 285 | |
Koselugo (selumetinib) — Worldwide product sales ($M)($M)6 | 177 | 170 | 163 | 224 | 137 | 138 | 165 | 119 | 114 | 132 | 85 | 87 | |
Other Rare Disease medicines — Worldwide product sales ($M)($M)6 | 74 | 74 | 55 | 64 | 55 | 58 | |||||||
Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M)($M)6 | 230 | 250 | 231 | 233 | 241 | 267 | 249 | 265 | 267 | 293 | 266 | 297 | |
Other Medicines (Established / Legacy Brands) — Worldwide YoY actual (%)(%) | -4.0% | -7.0% | -7.0% | -12.0% | -10.0% | -9.0% | -6.0% | -11.0% | -11.0% | -6.0% | -30.0% | -27.0% | |
Other Medicines (Established / Legacy Brands) — Worldwide YoY CER (%)(%) | -6.0% | -9.0% | -7.0% | -12.0% | -9.0% | -5.0% | -4.0% | -7.0% | -5.0% | 1.0% | -28.0% | -22.0% | |
Other Medicines (Established / Legacy Brands) — US product sales ($M)($M)1 | 19 | 23 | 14 | 9 | 21 | 19 | 24 | 35 | 28 | 24 | 29 | 36 | |
Other Medicines (Established / Legacy Brands) — US YoY (%)(%) | -9.0% | 22.0% | -41.0% | -73.0% | -26.0% | -20.0% | -18.0% | -3.0% | -13.0% | -33.0% | -9.0% | -3.0% | |
Other Medicines (Established / Legacy Brands) — Emerging Markets product sales ($M)($M)2 | 166 | 192 | 168 | 172 | 186 | 206 | 171 | 179 | 179 | 206 | 151 | 190 | |
Other Medicines (Established / Legacy Brands) — Emerging Markets YoY actual (%)(%) | -10.0% | -7.0% | -2.0% | -4.0% | 4.0% | 0.0% | 14.0% | -6.0% | -3.0% | 0.0% | -16.0% | -11.0% | |
Other Medicines (Established / Legacy Brands) — Emerging Markets YoY CER (%)(%) | -13.0% | -9.0% | -1.0% | -3.0% | 5.0% | 4.0% | 17.0% | 0.0% | 5.0% | 11.0% | -13.0% | -4.0% | |
Other Medicines (Established / Legacy Brands) — Europe product sales ($M)($M)2 | 25 | 15 | 25 | 23 | 16 | 19 | 28 | 22 | 24 | 29 | 38 | 19 | |
Other Medicines (Established / Legacy Brands) — Europe YoY actual (%)(%) | 52.0% | -23.0% | -10.0% | 4.0% | -32.0% | -35.0% | -27.0% | 18.0% | -7.0% | 31.0% | 36.0% | -32.0% | |
Other Medicines (Established / Legacy Brands) — Europe YoY CER (%)(%) | 51.0% | -30.0% | -14.0% | 3.0% | -38.0% | -30.0% | -28.0% | 16.0% | -7.0% | 30.0% | 34.0% | -34.0% | |
Other Medicines (Established / Legacy Brands) — Established RoW product sales ($M)($M)2 | 20 | 20 | 24 | 29 | 18 | 23 | 26 | 29 | 36 | 34 | 48 | 52 | |
Other Medicines (Established / Legacy Brands) — Established RoW YoY actual (%)(%) | 12.0% | -15.0% | -8.0% | 0.0% | -50.0% | -32.0% | -46.0% | -45.0% | -38.0% | -31.0% | -66.0% | -59.0% | |
Other Medicines (Established / Legacy Brands) — Established RoW YoY CER (%)(%) | 14.0% | -17.0% | -6.0% | -4.0% | -50.0% | -29.0% | -45.0% | -41.0% | -32.0% | -25.0% | -65.0% | -56.0% | |
Total projects in clinical development pipeline (count)3 | 183 | 186 | 197 | 198 | 196 | 194 | 191 | 199 | 189 | 182 | 178 | ||
Phase II & Phase III NME or major LCM projects in pipeline (count) | 116 | 118 | 125 | 122 | 132 | 132 | 130 | 139 | 131 | 123 | 123 | ||
New Molecular Entities (NMEs) in late-stage pipeline (count) | 21 | 21 | 20 | 20 | 19 | 18 | 19 | 21 | 20 | 19 | 17 | ||
Regulatory approvals in major markets — US, EU, China, Japan (count) | 15 | 14 | 7 | 12 | 8 | 16 | 6 | 9 | 7 | 9 | |||
Core gross profit ($M)($M)5 | 12,863 | 12,624 | 12,334 | 12,417 | 11,914 | 11,365 | 12,089 | 11,112 | 10,780 | 10,491 | 9,738 | 9,444 | |
Core gross margin (% of product sales)(%) | 84.0% | 83.0% | 80.0% | 82.0% | 82.0% | 84.0% | |||||||
Core gross profit YoY actual (%)(%) | 8.0% | 11.0% | 2.0% | 12.0% | 11.0% | 8.0% | 24.0% | 18.0% | 13.0% | 15.0% | 11.0% | 6.0% | |
Core gross profit YoY CER (%)(%) | 6.0% | 9.0% | 0.0% | 10.0% | 11.0% | 10.0% | 26.0% | 21.0% | 17.0% | 18.0% | 11.0% | 7.0% | |
Reported (IFRS) gross profit ($M)($M) | 12,861 | 12,610 | 12,385 | 12,390 | 11,984 | 11,347 | 12,166 | 10,484 | 10,755 | 10,461 | 9,716 | 9,397 | |
Reported (IFRS) gross margin (%)(%) | 84.0% | 82.0% | 80.0% | 82.0% | 83.0% | 84.0% | |||||||
Core R&D expense ($M)($M)5 | -3,662 | -3,461 | -3,731 | -3,550 | -3,453 | -3,088 | -3,573 | -3,068 | -2,872 | -2,698 | -2,914 | -2,485 | |
Core R&D expense (% of total revenue)(%) | 24.0% | 23.0% | 24.0% | 23.0% | 24.0% | 23.0% | |||||||
Core R&D expense YoY actual (%)(%) | 6.0% | 12.0% | 4.0% | 16.0% | 20.0% | 14.0% | 23.0% | 23.0% | 12.0% | 17.0% | 15.0% | 5.0% | |
Core R&D expense YoY CER (%)(%) | 5.0% | 8.0% | 3.0% | 14.0% | 18.0% | 16.0% | 22.0% | 24.0% | 13.0% | 18.0% | 14.0% | 5.0% | |
Reported (IFRS) R&D expense ($M)($M) | -4,053 | -3,492 | -3,862 | -3,663 | -3,548 | -3,159 | -4,677 | -3,115 | -3,008 | -2,783 | -3,073 | -2,584 | |
Reported (IFRS) R&D expense (% of total revenue)(%) | 26.0% | 23.0% | 25.0% | 24.0% | 25.0% | 23.0% | |||||||
Core SG&A expense ($M)($M)7 | -4,050 | -3,859 | -4,453 | -3,822 | -3,802 | -3,457 | -4,275 | -3,605 | -3,735 | -3,413 | -4,034 | -3,355 | |
Core SG&A expense (% of total revenue)(%) | 26.0% | 25.0% | 29.0% | 25.0% | 26.0% | 25.0% | |||||||
Core SG&A expense YoY actual (%)(%) | 7.0% | 12.0% | 4.0% | 6.0% | 2.0% | 1.0% | 6.0% | 8.0% | 13.0% | 12.0% | 13.0% | 6.0% | |
Core SG&A expense YoY CER (%)(%) | 4.0% | 7.0% | 2.0% | 4.0% | 1.0% | 4.0% | 7.0% | 9.0% | 16.0% | 13.0% | 12.0% | 7.0% | |
Reported (IFRS) SG&A expense ($M)($M) | -5,651 | -4,920 | -5,492 | -5,085 | -4,864 | -4,492 | -5,410 | -5,143 | -4,929 | -4,495 | -5,371 | -4,800 | |
Reported (IFRS) SG&A expense (% of total revenue)(%) | 37.0% | 32.0% | 35.0% | 33.0% | 34.0% | 33.0% | |||||||
Core distribution expense ($M)($M) | -145 | -141 | -153 | -148 | -146 | -132 | -143 | -145 | -132 | -135 | -145 | -129 | |
Core other operating income & expense ($M)($M) | 152 | 189 | 101 | 96 | 71 | 115 | 101 | 24 | 60 | 65 | 107 | 70 | |
Core operating profit ($M)($M)7 | 5,158 | 5,352 | 4,098 | 4,993 | 4,584 | 4,803 | 4,199 | 4,318 | 4,101 | 4,310 | 2,752 | 3,545 | |
Core operating margin (% of total revenue)(%) | 34.0% | 35.0% | 26.0% | 33.0% | 32.0% | 35.0% | 28.0% | 32.0% | 32.0% | 34.0% | 22.9% | 30.8% | |
Core operating profit YoY actual (%)(%) | 12.0% | 11.0% | -2.0% | 16.0% | 12.0% | 11.0% | 53.0% | 22.0% | -4.0% | 9.0% | 5.0% | 4.0% | |
Core operating profit YoY CER (%)(%) | 10.0% | 12.0% | -5.0% | 13.0% | 14.0% | 12.0% | 58.0% | 27.0% | 1.0% | 15.0% | 6.0% | 9.0% | |
Reported (IFRS) operating profit ($M)($M) | 3,164 | 4,246 | 2,978 | 3,583 | 3,508 | 3,674 | 2,036 | 2,106 | 2,746 | 3,115 | 1,234 | 1,954 | |
Reported (IFRS) operating margin (%)(%) | 21.0% | 28.0% | 19.0% | 24.0% | 24.0% | 27.0% | 14.0% | 16.0% | 21.0% | 25.0% | 10.3% | 17.0% | |
Core adjustment — Total restructuring charges ($M)($M) | -100 | -60 | -57 | -79 | 21 | -122 | -100 | -705 | -154 | -195 | -115 | -124 | |
Core adjustment — Intangible asset amortisation & impairments ($M)($M) | -1,546 | -990 | -1,124 | -1,181 | -1,047 | -975 | -2,003 | -1,469 | -987 | -955 | -1,007 | -1,014 | |
Core EPS ($ per share)($)5 | 2.63 | 2.58 | 2.12 | 2.38 | 2.17 | 2.49 | 2.09 | 2.08 | 1.98 | 2.06 | 1.45 | 1.73 | |
Core EPS YoY actual (%)(%) | 21.0% | 4.0% | 1.0% | 14.0% | 10.0% | 21.0% | 44.0% | 20.0% | -8.0% | 7.0% | 5.0% | 4.0% | |
Core EPS YoY CER (%)(%) | 18.0% | 5.0% | -2.0% | 12.0% | 12.0% | 21.0% | 49.0% | 27.0% | -3.0% | 13.0% | 7.0% | 9.0% | |
Reported (IFRS) basic EPS ($ per share)($) | 1.61 | 1.99 | 1.50 | 1.64 | 1.58 | 1.88 | 0.97 | 0.92 | 1.24 | 1.41 | 0.62 | 0.89 | |
Core net finance expense ($M)($M) | -340 | -281 | -269 | -305 | -303 | -215 | -310 | -329 | -285 | -245 | -259 | -223 | |
Core income tax expense ($M)($M) | -731 | -1,058 | -543 | -1,002 | -911 | -714 | -640 | -753 | -741 | -867 | -242 | -624 | |
EBITDA ($M)($M)1 | 5,092 | 5,612 | 4,489 | 5,132 | 4,897 | 4,958 | 4,373 | 3,923 | 4,025 | 4,370 | 2,561 | 3,236 | |
Depreciation, amortisation & impairment added back in EBITDA ($M)($M) | 1,928 | 1,366 | 1,511 | 1,549 | 1,389 | 1,284 | 2,337 | 1,817 | 1,279 | 1,255 | 1,327 | 1,282 | |
FX sensitivity (+5% vs USD): EUR impact on annual Total Revenue ($M)($M)14 | 499 | 499 | 499 | -461 | -461 | -461 | -461 | 397 | 397 | 397 | 397 | 323 | |
Net intangible assets carrying value ($M)($M) | 37,723 | 37,846 | 37,925 | 37,177 | 39,426 | 38,089 | |||||||
Total inventories carrying value ($M)($M) | 6,932 | 6,557 | 6,467 | 5,288 | 5,667 | 5,424 | |||||||
Property, plant and equipment (PP&E) — net carrying value ($M)($M) | 13,615 | 12,962 | 11,637 | 10,252 | 9,630 | 9,402 | |||||||
Right-of-use (ROU) lease assets — net carrying value ($M)($M) | 2,685 | 1,741 | 1,592 | 1,395 | 1,203 | 1,100 | |||||||
Net debt ($M)($M)3 | 26,912 | 25,944 | 23,374 | 23,965 | 25,227 | 26,067 | 24,570 | 26,348 | 26,324 | 26,449 | 22,510 | 23,371 | |
Total cash, cash equivalents & current investments ($M)($M)2 | 4,968 | 7,675 | 5,741 | 8,182 | 7,108 | 5,395 | 5,654 | 4,930 | 7,076 | 8,021 | 5,962 | 5,115 | |
Cash and cash equivalents ($M)($M) | 4,893 | 7,560 | 5,711 | 8,143 | 7,058 | 5,230 | 5,488 | 4,797 | 6,916 | 7,841 | 5,840 | 4,871 | |
Other current fixed-income investments ($M)($M) | 75 | 115 | 30 | 39 | 50 | 165 | 166 | 133 | 160 | 180 | 122 | 244 | |
Total gross debt (loans, bonds, overdrafts & lease liabilities) ($M)($M)4 | -32,239 | -33,918 | -29,622 | -32,632 | -32,839 | -31,646 | -30,295 | -31,562 | -33,533 | -34,551 | -28,622 | -28,576 | |
Non-current loans & bonds ($M)($M) | -23,683 | -24,454 | -24,715 | -24,700 | -24,714 | -26,692 | -26,506 | -28,887 | -27,225 | -27,259 | -22,365 | -22,225 | |
Current portion of loans & bonds ($M)($M) | -2,859 | -4,567 | -2,460 | -4,461 | -4,461 | -2,010 | -2,007 | -12 | -2,018 | -4,593 | -4,614 | -4,857 | |
Lease liabilities ($M)($M) | -2,748 | -1,888 | -1,803 | -1,758 | -1,633 | -1,551 | -1,452 | -1,422 | -1,241 | -1,242 | -1,128 | -979 | |
Short-term borrowings & bank overdrafts ($M)($M) | -542 | -597 | -644 | -622 | -561 | -445 | -330 | -769 | -596 | -477 | -515 | -515 | |
Net financial derivatives fair value in Net Debt ($M)($M) | 359 | 299 | 507 | 485 | 504 | 184 | 71 | 284 | 133 | 81 | 150 | 90 | |
Net cash inflow from operating activities ($M)($M)7 | 2,865 | 3,359 | 2,342 | 5,134 | 3,386 | 3,713 | 2,907 | 3,383 | 3,085 | 2,486 | 2,380 | 3,114 | |
Net cash inflow before financing activities ($M)($M) | -47 | 1,567 | 896 | 3,133 | 1,278 | 2,460 | 1,726 | 1,869 | 213 | 73 | 1,303 | 1,893 | |
Movement in working capital & short-term provisions ($M)($M) | -438 | -1,000 | -1,201 | 835 | -345 | -426 | -350 | 41 | -129 | -455 | |||
Income tax paid ($M)($M) | -1,525 | -526 | -652 | -644 | -1,186 | -363 | -772 | -641 | -907 | -430 | -656 | -649 | |
Interest paid ($M)($M) | -189 | -441 | -247 | -446 | -201 | -422 | -238 | -492 | -242 | -341 | -255 | -343 | |
Purchase of property, plant and equipment (Capex) ($M)($M) | -763 | -547 | -1,036 | -686 | -659 | -429 | -708 | -417 | -382 | -417 | -525 | -319 | |
Purchase of intangible assets ($M)($M) | -2,342 | -991 | -251 | -1,040 | -1,264 | -540 | -247 | -941 | -286 | -1,188 | -421 | -560 | |
Dividends paid to shareholders ($M)($M) | -1 | -3,287 | -3 | -1,611 | -10 | -3,347 | -3 | -1,576 | -17 | -3,033 | -2 | -1,410 | |
U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($M)1 | |||||||||||||
U.S. Personal Consumption Expenditures — Health Care Services, SAAR ($B)($M) | 3,790 | 3,700 | 3,667 | 3,615 | 3,530 | 3,465 | 3,418 | 3,358 | 3,288 | 3,244 | 3,159 | 3,079 | |
Consolidated Total Revenue ($M)($M)19 | 15,384 | 15,288 | 15,503 | 15,191 | 14,457 | 13,588 | 14,891 | 13,565 | 12,938 | 12,679 | 12,024 | 11,492 | |
Total assets ($M)($M)8 | 115,833 | 114,074 | 112,422 | 104,035 | 104,340 | 101,119 | |||||||
Net cash inflow from operating activities ($M)($M)3 | 2,865 | 3,359 | 2,342 | 5,134 | 3,386 | 3,713 | 2,907 | 3,383 | 3,085 | 2,486 | 2,380 | 3,114 | |
303 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar & IFRS reporting: AstraZeneca PLC (CIK 0000901832) reports under IFRS in millions of U.S. dollars ($M) with a fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026; monthly Total Voting Rights through September 30, 2026).
- Core operational & commercial KPIs (Groups 1–4) cover: (1) Revenue by stream (Product Sales $55,702M, Alliance Revenue $3,053M led by Enhertu $1,945M, Tezspire $630M, Beyfortus $284M & Datroway $49M, and Collaboration Revenue $701M in FY2025) and Regional Total Revenue across the US ($25,571M), Emerging Markets ($14,487M split into China $6,654M and Ex-China Emerging Markets $7,833M), Europe ($12,727M), and Established RoW ($5,954M) with published Actual YoY % and Constant Exchange Rate (CER) YoY % growth; (2) Product Sales across all 5 Therapy Areas (Oncology, CVRM, R&I, V&I/ID, Rare Disease) and 34 continuous medicines broken down by all 5 geographic regions (World, US, Emerging Markets, Europe, Established RoW); (3) U.S. Gross-to-Net (GTN) Sales Rebates, Chargebacks & Returns reconciliation (FY2025 Gross U.S. Product Sales of $47,385M less $23,941M total GTN deductions — including $13,963M Managed Care & Medicare, $5,113M Chargebacks, $2,527M Medicaid, $483M Cash Discounts, $149M Customer Returns, $99M Branded Prescription Drug Fee, and $1,607M Other — yielding $23,444M Net U.S. Product Sales), Global/US/China/Rare Disease rebate reserves, U.S. GTN sensitivity %, and Top 3 U.S. Wholesaler concentration (78% of U.S. trade receivables; #1 wholesaler $8,218M and #2 wholesaler $5,957M in FY2025); and (4) R&D Clinical Pipeline (183 total projects, 116 Phase II/III projects, 21 late-stage NMEs, and 15 regulatory approvals in Q2 2026), Clinical Trial Transparency, Research Animals, and U.S. FDA Inspections / Form 483 Observations / Recalls.
- Extended operational & financial KPIs (Groups 5–12) cover Core vs. Reported P&L & FX sensitivities (+5% impact of EUR, CNY, JPY, GBP, SEK on Total Revenue & Core Operating Profit), Individual Medicine Intangible Assets (C5 Soliris/Ultomiris $9,990M, Strensiq/Kanuma $5,375M, Alexion IPR&D $3,350M, Calquence $2,110M, Enhertu $2,188M, Baxdrostat $1,813M, Datroway $1,561M), Inventories by stage, PP&E by country, Provisions rollforward, Partner Payables to Daiichi Sankyo & Bond Avillion, Monthly Total Voting Rights (1,551,053,289 shares at Sep 2026), Net Debt ($26,912M at Q2 2026), Subsidiary & Statutory Entity self-disclosures (AstraZeneca UK Limited, MedImmune UK Limited, and the $9.63B AstraZeneca US 401(k) Plan from Form 11-K), Global Workforce (96,800 employees at FY2025), Share Plans (PSP/GRSP/RSP), Defined Benefit Pensions (UK, Sweden, Other), Access to Healthcare reach (108M people), Scope 1/2/3 GHG emissions, FRED industry benchmarks, and Consolidated Financial Statements (with Q1/Q3/Q4 backfill).
- Parent-only standalone financial statements in the UK Annual Report are prepared under FRS 101 (UK GAAP) on an annual-only basis for AstraZeneca PLC as a non-trading holding company ($0 product sales), so Consolidated − Standalone subtraction is not applicable. All values are strictly as published (with verbatim quotes on hover for text-extracted cells), plus period-splitting (Q2 = H1 − Q1; Q3 = 9M − H1; Q4 = FY − 9M) displayed in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (325)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets YoY actual (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets YoY CER (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW YoY actual (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW YoY CER (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Emerging Markets product sales ($M) › Truqap (capivasertib) — Emerging Markets YoY actual (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Emerging Markets product sales ($M) › Truqap (capivasertib) — Emerging Markets YoY CER (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Europe product sales ($M) › Truqap (capivasertib) — Europe YoY actual (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Europe product sales ($M) › Truqap (capivasertib) — Europe YoY CER (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Established RoW product sales ($M) › Truqap (capivasertib) — Established RoW YoY actual (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Established RoW product sales ($M) › Truqap (capivasertib) — Established RoW YoY CER (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide YoY actual (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide YoY CER (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — US product sales ($M) › Faslodex (fulvestrant) — US YoY (%)
- Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Emerging Markets product sales ($M) › Faslodex (fulvestrant) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Emerging Markets product sales ($M) › Faslodex (fulvestrant) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Europe product sales ($M) › Faslodex (fulvestrant) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Europe product sales ($M) › Faslodex (fulvestrant) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Established RoW product sales ($M) › Faslodex (fulvestrant) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Established RoW product sales ($M) › Faslodex (fulvestrant) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — US product sales ($M) › Orpathys (savolitinib) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Emerging Markets product sales ($M) › Orpathys (savolitinib) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Emerging Markets product sales ($M) › Orpathys (savolitinib) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Europe product sales ($M) › Orpathys (savolitinib) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Europe product sales ($M) › Orpathys (savolitinib) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Established RoW product sales ($M) › Orpathys (savolitinib) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Established RoW product sales ($M) › Orpathys (savolitinib) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — US product sales ($M) › Iressa (gefitinib) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Emerging Markets product sales ($M) › Iressa (gefitinib) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Emerging Markets product sales ($M) › Iressa (gefitinib) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Europe product sales ($M) › Iressa (gefitinib) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Europe product sales ($M) › Iressa (gefitinib) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Established RoW product sales ($M) › Iressa (gefitinib) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Established RoW product sales ($M) › Iressa (gefitinib) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — US product sales ($M) › Casodex (bicalutamide) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Emerging Markets product sales ($M) › Casodex (bicalutamide) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Emerging Markets product sales ($M) › Casodex (bicalutamide) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Europe product sales ($M) › Casodex (bicalutamide) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Europe product sales ($M) › Casodex (bicalutamide) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Established RoW product sales ($M) › Casodex (bicalutamide) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Established RoW product sales ($M) › Casodex (bicalutamide) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — US product sales ($M) › Arimidex (anastrozole) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Emerging Markets product sales ($M) › Arimidex (anastrozole) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Emerging Markets product sales ($M) › Arimidex (anastrozole) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Europe product sales ($M) › Arimidex (anastrozole) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Europe product sales ($M) › Arimidex (anastrozole) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Established RoW product sales ($M) › Arimidex (anastrozole) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Drugs by 5 Geographic Regions › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Established RoW product sales ($M) › Arimidex (anastrozole) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — US product sales ($M) › Etcamah (launched Q2 2026) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Europe product sales ($M) › Etcamah (launched Q2 2026) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Europe product sales ($M) › Etcamah (launched Q2 2026) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Established RoW product sales ($M) › Etcamah (launched Q2 2026) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Established RoW product sales ($M) › Etcamah (launched Q2 2026) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Emerging Markets product sales ($M) › Wainua (eplontersen) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Emerging Markets product sales ($M) › Wainua (eplontersen) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Europe product sales ($M) › Wainua (eplontersen) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Europe product sales ($M) › Wainua (eplontersen) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — US product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Areas › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — US product sales ($M) › Bydureon (exenatide ER) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Emerging Markets product sales ($M) › Bydureon (exenatide ER) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Emerging Markets product sales ($M) › Bydureon (exenatide ER) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Europe product sales ($M) › Bydureon (exenatide ER) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Europe product sales ($M) › Bydureon (exenatide ER) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Established RoW product sales ($M) › Bydureon (exenatide ER) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Established RoW product sales ($M) › Bydureon (exenatide ER) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — US product sales ($M) › Onglyza (saxagliptin) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Emerging Markets product sales ($M) › Onglyza (saxagliptin) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Emerging Markets product sales ($M) › Onglyza (saxagliptin) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Europe product sales ($M) › Onglyza (saxagliptin) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Europe product sales ($M) › Onglyza (saxagliptin) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Established RoW product sales ($M) › Onglyza (saxagliptin) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Established RoW product sales ($M) › Onglyza (saxagliptin) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — US product sales ($M) › Byetta (exenatide) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Emerging Markets product sales ($M) › Byetta (exenatide) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Emerging Markets product sales ($M) › Byetta (exenatide) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Europe product sales ($M) › Byetta (exenatide) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Europe product sales ($M) › Byetta (exenatide) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Established RoW product sales ($M) › Byetta (exenatide) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Established RoW product sales ($M) › Byetta (exenatide) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — US product sales ($M) › Atacand (candesartan) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Emerging Markets product sales ($M) › Atacand (candesartan) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Emerging Markets product sales ($M) › Atacand (candesartan) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Europe product sales ($M) › Atacand (candesartan) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Europe product sales ($M) › Atacand (candesartan) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Established RoW product sales ($M) › Atacand (candesartan) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Established RoW product sales ($M) › Atacand (candesartan) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — US product sales ($M) › Other Diabetes medicines — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Emerging Markets product sales ($M) › Other Diabetes medicines — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Emerging Markets product sales ($M) › Other Diabetes medicines — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Europe product sales ($M) › Other Diabetes medicines — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Europe product sales ($M) › Other Diabetes medicines — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Established RoW product sales ($M) › Other Diabetes medicines — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Established RoW product sales ($M) › Other Diabetes medicines — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — US product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — US product sales ($M) › Daliresp / Daxas (roflumilast) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Europe product sales ($M) › Daliresp / Daxas (roflumilast) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Europe product sales ($M) › Daliresp / Daxas (roflumilast) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — US product sales ($M) › Other Vaccines & Immune Therapies — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Europe product sales ($M) › Other Vaccines & Immune Therapies — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Europe product sales ($M) › Other Vaccines & Immune Therapies — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Synagis (palivizumab) — Worldwide product sales ($M) › Synagis (palivizumab) — US product sales ($M) › Synagis (palivizumab) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — US product sales ($M) › Evusheld (tixagevimab/cilgavimab) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines by 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — US product sales ($M) › Vaxzevria / COVID-19 Vaccine — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — US product sales ($M) › COVID-19 mAbs & vaccine combined — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Europe product sales ($M) › COVID-19 mAbs & vaccine combined — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Europe product sales ($M) › COVID-19 mAbs & vaccine combined — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Emerging Markets product sales ($M) › Other Rare Disease medicines — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Emerging Markets product sales ($M) › Other Rare Disease medicines — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Established RoW product sales ($M) › Other Rare Disease medicines — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Established RoW product sales ($M) › Other Rare Disease medicines — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — US product sales ($M) › Kanuma (sebelipase alfa) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Europe product sales ($M) › Kanuma (sebelipase alfa) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Europe product sales ($M) › Kanuma (sebelipase alfa) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Established RoW product sales ($M) › Kanuma (sebelipase alfa) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Established RoW product sales ($M) › Kanuma (sebelipase alfa) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Other Established / Legacy Medicines — Worldwide product sales ($M) › Other Established / Legacy Medicines — US product sales ($M) › Other Established / Legacy Medicines — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — US product sales ($M) › Losec / Prilosec (omeprazole) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Europe product sales ($M) › Losec / Prilosec (omeprazole) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Europe product sales ($M) › Losec / Prilosec (omeprazole) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — US product sales ($M) › Seroquel XR / IR (quetiapine) — US YoY (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — US product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Europe product sales ($M) › Seroquel XR / IR (quetiapine) — Europe YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Europe product sales ($M) › Seroquel XR / IR (quetiapine) — Europe YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Europe product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW YoY actual (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW YoY CER (%)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW product sales ($M)
- Product Sales by Disease Area & 34 Detailed Medicines across 5 Geographic Regions › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M)
- Intangible Assets by Medicine, Inventories, PP&E, Legal Provisions & Tax › Net intangible assets carrying value ($M) › Medicine intangible — MSD / Merck alliance option & co-promotion ($M)
- U.S. Pharmaceutical Industry & Healthcare Spending Context (FRED / BLS / Census / BEA) › U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($M) › U.S. Retail Sales — Pharmacies and Drug Stores, Not Seasonally Adjusted ($M)
- U.S. Pharmaceutical Industry & Healthcare Spending Context (FRED / BLS / Census / BEA) › U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($M)
- Epidemiology Data Tables › Patient prevalence & incidence across Oncology / CVRM / R&I / Rare Disease (Missing FY2025 between FY2024 and FY2026, causing a break in the annual series)
- Form 6-K Block Listing Six-Monthly Interim Reviews (2021–2026) › Unallotted share balances under employee share schemes (Disclosed semi-annually, irregular quarterly/annual periods)
Dữ liệu cập nhật 2026-10-28.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Core — Revenue Structure (Product Sales, Alliance Revenue, Collaboration) & Revenue by Geographic Market
Core — Product Sales by Therapy Area & 34 Detailed Medicines across 5 Geographic Regions
- Oncology — Worldwide product sales ($M) ($M)42 kỳ
- Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) ($M)42 kỳ
- Respiratory & Immunology (R&I) — Worldwide product sales ($M) ($M)42 kỳ
- Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) ($M)18 kỳ
- Rare Disease (Alexion) — Worldwide product sales ($M) ($M)20 kỳ
- Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) ($M)42 kỳ
Core — US Gross-to-Net (GTN) Deductions, Return Provisions & US Wholesaler Concentration
Core — R&D Progress, Clinical Pipeline (Clinical Trials Appendix), Trials & Manufacturing Quality (FDA)
- Total projects in clinical development pipeline (count)11 kỳ
- Cumulative clinical trials with de-identified patient-level data shared (trials)4 kỳ
- Total animals used in preclinical research & regulatory testing (animals)4 kỳ
- U.S. FDA site inspections conducted across manufacturing & R&D network (inspections)4 kỳ
Extended — Operating Performance Core vs. Reported, Profit Margins, EBITDA & Foreign Exchange (FX) Sensitivity
Extended — Intangible Assets by Medicine, Inventory, PP&E, Legal Provisions & Taxes
- Net intangible assets carrying value ($M) ($M)21 kỳ
- Total inventories carrying value ($M) ($M)21 kỳ
- Property, plant and equipment (PP&E) — net carrying value ($M) ($M)21 kỳ
- Right-of-use (ROU) lease assets — net carrying value ($M) ($M)16 kỳ
- Total provisions (current + non-current) ($M) ($M)7 kỳ
- Collaboration partner payables — Daiichi Sankyo (Enhertu & Datroway) non-current ($M) ($M)2 kỳ
- Total undiscounted contractual maturity of financial liabilities ($M) ($M)6 kỳ
- Tax benefit from UK/Swedish IP Incentive (Patent Box) regimes ($M) ($M)5 kỳ
Extended — Monthly Outstanding Shares & Voting Rights (Form 6-K TVR), Net Debt & Cash Flows
Subsidiaries & Self-Disclosed Legal Entities — AstraZeneca UK Ltd, MedImmune UK Ltd (UK GPGR) & US 401(k) Retirement Plan (Form 11-K)
Extended — Global Workforce, Share-Based Compensation (PSP/GRSP/RSP) & Defined Benefit Pension Plans
Extended — Global Access to Healthcare & Environmental / Sustainability (ESG Data Annex)
- Cumulative people reached through Access to Healthcare programmes (millions) (M)4 kỳ
- Total Scope 1 & Scope 2 (market-based) GHG emissions (tCO2e)5 kỳ
- Total Scope 3 value-chain GHG emissions (tCO2e)5 kỳ
- Total energy consumption across global sites & fleet (MWh)3 kỳ
- Total global water withdrawal across manufacturing & R&D sites (m3)5 kỳ
Pharmaceutical Industry Context & US Healthcare Spending (FRED / BLS / Census / BEA)
Consolidated Financial Statements & Geographic Segments (from financial statements, supplemented for missing quarters)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của AstraZeneca
- Form 6-K FY2026Q2 Earnings Release ↗
- Form 6-K FY2025Q4 Earnings Release ↗
- Form 6-K (filed 2026-07-27) ↗
- Form 20-F (filed 2026-02-24) ↗
- Clinical Trials Appendix (2026Q2) ↗
- Clinical Trials Appendix (2025Q4) ↗
- Form 6-K Total Voting Rights (2026-10-01) ↗
- Form 11-K FY2025 (AstraZeneca US 401(k) Plan) ↗
- FRED / U.S. Bureau of Labor Statistics (PCU325412325412) ↗
See a number that looks wrong?